← Back to Search

Artificial Intelligence Care Coach for Dementia Caregivers

N/A
Recruiting
Led By Cameron Gettel
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥65 years with a diagnosis of dementia within the electronic health record OR new cognitive impairment identified during an ED visit
Discharge after an ED visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a computer program that helps caregivers when older adults with memory problems leave the emergency room. The program aims to make the transition from hospital to home smoother by offering guidance and support. It focuses on caregivers because they play a key role in managing the care of these patients.

Who is the study for?
This trial is for caregivers of older adults aged 65 or above with dementia or new cognitive impairment identified during an ED visit. Participants must speak English or Spanish, be discharged after an ED visit, and have a smart device with internet to use the NeuViCare AI services. Those showing signs of delirium are not eligible.
What is being tested?
The study is testing the NeuViCare application, which uses artificial intelligence to help manage care transitions after older adults with cognitive impairments are discharged from the emergency department.
What are the potential side effects?
Since this trial involves using an AI-based application rather than medication, traditional side effects like those seen in drug trials may not apply. However, users might experience stress or frustration if they encounter technical difficulties.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 or older and have been diagnosed with dementia or noticed new memory problems.
Select...
I was recently discharged from the emergency department.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 30 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability of Intervention Measure
Feasibility of Intervention Measure
Intervention Appropriateness Measure
+1 more
Secondary study objectives
Dementia Knowledge Assessment Scale
Emergency Department revisits
General Self-Efficacy Scale
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intervention (NeuViCare AI)Experimental Treatment1 Intervention
An anticipated 55 participants will be part of the Intervention arm participants and will engage with NeuViCare AI, including all variations of its 5 components described further below.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for dementia include pharmacological approaches like cholinesterase inhibitors and memantine, which work by enhancing neurotransmitter activity to improve cognitive function. Non-pharmacological treatments, such as AI-enhanced discharge care transitions, provide tailored support and information to caregivers, helping manage symptoms and improve the quality of life for both patients and caregivers. These treatments are essential as they address the holistic needs of dementia patients, ensuring comprehensive care that supports cognitive and emotional well-being.
An intervention to promote self-management, independence and self-efficacy in people with early-stage dementia: the Journeying through Dementia RCT.Supporting self-care of long-term conditions in people with dementia: A systematic review.Recruiting Dementia Caregivers Into Clinical Trials: Lessons Learnt From the Australian TRANSCENDENT Trial.

Find a Location

Who is running the clinical trial?

West Health InstituteUNKNOWN
National Institute on Aging (NIA)NIH
1,782 Previous Clinical Trials
28,184,038 Total Patients Enrolled
292 Trials studying Dementia
23,634,818 Patients Enrolled for Dementia
Emergency Medicine FoundationOTHER
17 Previous Clinical Trials
2,188 Total Patients Enrolled

Media Library

Intervention (NeuViCare AI) Clinical Trial Eligibility Overview. Trial Name: NCT05352399 — N/A
Dementia Research Study Groups: Intervention (NeuViCare AI)
Dementia Clinical Trial 2023: Intervention (NeuViCare AI) Highlights & Side Effects. Trial Name: NCT05352399 — N/A
Intervention (NeuViCare AI) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05352399 — N/A
~3 spots leftby Dec 2024